Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
Acquisition focused on clinical-stage program potravitug, a first-in-class BK polyomavirus monoclonal antibody
July 1, 2026